MUVON Therapeutics
MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich, developing a therapeutic platform for skeletal muscle tissue regeneration based on autologous cells. Their mission is to provide safe, effective, and affordable treatments for debilitating diseases, initially focusing on stress urinary incontinence in women. They aim to develop personalized regenerative treatments to extend human health-span and address high unmet medical needs caused by muscle damage or degradation.
Industries
Nr. of Employees
small (1-50)
MUVON Therapeutics
Zürich, Zurich, Switzerland, Europe
Products
Autologous Muscle Tissue Regeneration
A therapy platform for skeletal muscle regeneration using the patient's own muscle precursor cells, targeting diseases like stress urinary incontinence.
Phase II Clinical Trial for Stress Urinary Incontinence
An ongoing clinical trial investigating the efficacy of autologous muscle tissue regeneration therapy in women with stress urinary incontinence.
Good Manufacturing Practice (GMP) Compliance
Ensures the production process of therapies meets the required quality standards.
Good Clinical Practice (GCP) Compliance
Ensures clinical trials are conducted according to ethical and scientific quality standards.
Autologous Muscle Tissue Regeneration
A therapy platform for skeletal muscle regeneration using the patient's own muscle precursor cells, targeting diseases like stress urinary incontinence.
Phase II Clinical Trial for Stress Urinary Incontinence
An ongoing clinical trial investigating the efficacy of autologous muscle tissue regeneration therapy in women with stress urinary incontinence.
Good Manufacturing Practice (GMP) Compliance
Ensures the production process of therapies meets the required quality standards.
Good Clinical Practice (GCP) Compliance
Ensures clinical trials are conducted according to ethical and scientific quality standards.